Heart Failure, Shock and Hemodynamics Howard Sacher D.O. Long Island Cardiology.

Slides:



Advertisements
Similar presentations
HEART FAILURE (HF) Heart failure is the pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to.
Advertisements

ARTERIAL BLOOD PRESSURE REGULATION
Ionotropic Therapy in Acute Heart Failure
Lecture:10 Contractility, Stroke volume and Heart Failure
Advanced Heart Failure: My Approach
A Look Into Congestive Heart Failure By Tim Gault.
Congestive Heart Failure
 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
 By the end of this lecture the students are expected to:  Define cardiac output, stroke volume, end- diastolic and end-systolic volumes.  Define physiological.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 43 Review of Hemodynamics.
GROUP 4.
Neurohormonal Activation especially AVP in Congestive Heart Failure 陈宇寰 丁 宁 高 柳 郭华秋 韩国嵩 臧 鹏.
Heart Failure, Shock and Hemodynamics Howard Sacher D.O. Long Island Cardiology.
Regulation and Integration
1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –
Diseases of the Cardiovascular System Ischemic Heart Disease – Myocardial Infartcion – Sudden Cardiac Death – Heart Failure – Stroke + A Tiny Bit on the.
BLOOD PRESSURE - PHYSIOLOGY ROBYN DANE AND KATY DAVIDSON.
Bio-Med 350 Normal Heart Function and Congestive Heart Failure.
Heart Failure Dr. Meg-angela Christi M. Amores. The term "cardiac failure" means simply failure of the heart to pump enough blood to satisfy the needs.
Blood Pressure Regulation 2
Cardiovascular Dynamics During Exercise
2013 Cardiac output 1 Cardiac Output Prof. K. Sivapalan.
HEART FAILURE PROF. DR. MUHAMMAD AKBAR CHAUDHRY M.R.C.P.(U.K) F.R.C.P.(E) F.R.C.P.(LONDON) F.A.C.C. DESIGNED AT A.V. DEPTT F.J.M.C. BY RABIA KAZMI.
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
CONCEPTS OF NORMAL HEMODYNAMICS AND SHOCK
CARDIAC AND VASCULAR FUNCTION CURVES.. Figure Length-force relationships in intact heart: a Frank-Starling curve Optimal Length.
Treatment of Heart Failure Claire Hunter, MD. Treatment of Heart Failure Goals Improve quality of life Prolong life Ejection fraction most important.
 By the end of this lecture the students are expected to:  Understand the concept of preload and afterload.  Determine factors affecting the end-diastolic.
Refractory period of cardiac muscle cardiac muscle has refractory period, preventing restimulation cardiac muscle has refractory period, preventing restimulation.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
2nd phase medicine Cardiovascular Homeostasis 2 nd Phase Medicine CVS Module.
Blood Pressure Required to move blood and all its constituents throughout the body.
Blood Pressure Clinical Science Applied to Nursing CopyrightCSAN2005CardiffUniversity.
kvs1ed.ppt 1 Heart and Circulatory Failure Lectures from Pathological Physiology Dental Medicine Study materials from Pathological Physiology,
Frank-Starling Mechanism
Nursing and heart failure
 By the end of this lecture the students are expected to:  Define cardiac output, stroke volume, end- diastolic and end-systolic volumes.  Define.
1. Cardiac failure – a survey 2. Pathological overload of the heart 2.1 Volume overload 2.2 Pressure overload 3. Systolic and diastolic dysfunction 3.1.
Cardiac Output. Cardiac output The volume of blood pumped by either ventricle in one minute The output of the two ventricles are equal over a period of.
Blood Pressure Clinical Science Applied to Nursing CopyrightCSAN2005CardiffUniversity.
Chapter 13: Shock.
Antihypertensive Drugs
Haissam A Haddad, MD, FRCPC, FACC University of Ottawa Heart Institute
Blood Pressure Regulation 2
Heart Failure - I Pathophysiology Dr Hanan ALBackr 3/11/1429(1/11/2008)
Heart failure Laszlo L. Tornoci Inst. Pathophysiology Semmelweis University.
– Dr. J. Satish Kumar, MD, Department of Basic & Medical Sciences, AUST General Medicine CVS Name:________________________________________ Congestive Heart.
Heart Failure What is Heart Failure? The heart is not pumping properly.  Usually, the heart has been weakened by an underlying condition  Blocked arteries.
Basic Science Series: Pathophysiology of Heart Failure October 27/2009.
Exercise Management Chronic Heart Failure Chapter 12.
 By the end of this lecture the students are expected to:  Explain how cardiac contractility affect stroke volume.  Calculate CO using Fick’s principle.
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
Congestive heart failure Dr/Rehab Gwada. Objectives – Define Congestive Heart Failure. – Outlines the Factors Affecting Cardiac Output – Discuses the.
Cardiac Output April 28, 2017 Cardiac Output.
Heart Failure  Dfinition:  Clinical features  Underlying causes of HF include Arteriosclerotic heart disease, MI, hypertensive heart disease, valvular.
Congestive Heart Failure Dory Roedel Ferraro, DNP, ANP-BC, CBN.
Cardiovascular Dynamics Part 2 Biology 260. Maintaining Blood Pressure Requires – Cooperation of the heart, blood vessels, and kidneys – Supervision by.
1 Topics to be addressed: Blood Anatomy of Blood Vessels Anatomy of the Heart The Conduction System The Cardiac Cycle Cardiodynamics Blood Flow and its.
Pharmacotherapy Of Cardiovascular Disorders: Heart Failure
Heart Failure NURS 241 Chapter 35 (p.797).
Heart and Circulatory Failure
Anatomy & Physiology II
Blood Pressure Regulation 2
Circulatory shock.
به نام خدا Dominant Role of the Kidney in Long-Term Regulation of Arterial Pressure and in Hypertension: The Integrated System for Pressure Control.
LECTURE 22 BLOOD PRESSURE
Section III: Neurohormonal strategies in heart failure
The pathophysiology of myocardial infarction-induced heart failure
Blood Pressure Regulation
Khalid AlHabib Professor of Cardiac Sciences Cardiology Consultant
Presentation transcript:

Heart Failure, Shock and Hemodynamics Howard Sacher D.O. Long Island Cardiology

Learning Objectives To gain insight into the definition of, epidemiology of, pathophysiology of, changes in treatment recommendations for, clinical trials pertaining to, and prevention of ventricular dysfunction and heart failure. To understand the pathophysiology of heart failure with specific reference to the syndrome's molecular biodynamics, humoral, neurohumoral, and cytokine milieu.

Learning Objectives (cont.) To place in proper perspective the clinical trials that have shaped our contemporary heart failure therapeutic philosophies. To understand alternatives to pharmacologic therapies of heart failure.

Heart Failure Today’s perception of heart failure is quite different from that of only a few decades ago. Recent insight emphasizes the importance of neuro-endocrine, humoral, and inflammatory factors perpetuating heart failure originally precipitated by many disparate diseases.

Cont’d Heart failure should be not be considered a specific disease but rather a syndrome comprised of molecular genetic, organelle, contractile-protein and circulatory neurologic and humoral abnormalities that develop after a spectrum of diseases produce cardiac or circulatory injury. Heart failure patients can, in fact, be entirely asymptomatic Broadly the definitions allow earlier identification of at-risk populations so that intervention can begin earlier and attenuate the devestating morbidity and mortality of heart failure.

Cont’d Experimental and clinical trials now give clinicians guidance on the benefits and detriments of surgical and pharmaco-therapeutic strategies, allowing physicians to better diagnose and treat patients with heart failure. An integrated overview of the heart failure mileu shows that the molecular dynamics of the heart are critical to syndrome evolution Heart failure is a dynamic situation providing opportunity for both prevention and treatment.

Ventricular Dysfunction Is comprised of systolic and diastolic dysfunction The initial myocyte injury can be intrinsic as in cardiomyopathy of muscular dystrophy or extrinsic, as in anoxia (myocardial infarction), inflammation (lymphocytic myocarditis) or chemical toxins(anthracyclines).

Cont’d Resulting increase in interstitial matrix decomposition comprised of varying quantities of fibrin, collagen, and other ground substances effects diastolic cardiac properties making the heart much more stiff and therefore non- compliant. This plays a significant role in precipitating significant decline in global pump performance. It is not known if therapies currently used for heart failure have beneficial effects on this matrix or if they do to what degree.

Disease Processes Trigger the molecular genetic cellular physiologic and functional alterations that cause failure of systems, producing contractile dysfunction or impaired filling.

Hemodynamic Abnormalities Systolic and diastolic ventricular dysfunction then cause hemodynamic abnormalities that create flow volume and pressure derangements in the heart and systemic blood vessels

Compensatory Mechanisms A. Triggered by hemodynamic abnormalities are many and varied B. They include activation of the renin- angiotensin-aldosterone system (that ultimately induces salt and water retention and increased systemic vascular resistance) and sympathetic nervous system up-regulation (that augments cardiac contractility and increases heart rate, venous and arterial tone).

Hemodynamic Abnormalities of HF trigger many subsequent compensatory mechanisms designed to augment peripheral organ perfusion Increased sympathetic tone increases: –Contractility –HR –Venous and Arterial Tone –Pressure RAA system is upregulation Ventricular dilation and hypertrophy are compensatory mechanisms designed to augment SV and peripheral organ flow

Symptoms and Physical Findings As metabolic abnormalities and compensatory mechanisms intertwine, they create a variety of metabolic changes, symptoms, and physical findings. –Azotemia-prerenal due to hypoperfusion (decrease effective arterial volume) –Hyponatremia- decrease circulating volume leading to increased thirst and vasopressin, also diuretics without water restriction

Cont’d –Hypokalemia- diuretics –Hypomagnesemia- diuretics –Hyperuricemia- diuretics –Acidosis- hypoperfusion –Alkalosis- diuretics

Please see Essentials of Medicine, Cecil pg 49 Fig 5-6

Generally Pt’s dying from HF have either sudden cardiac death 2 nd to: –Fatal Arrhythmias Electrolyte Abnormalities Inc. serum catacholamines Ischemia –Developing significant systemic hypoperfusion Congestion Low Cardiac Output

Basic Elements of Heart Failure Syndrome Impaired contractility cause depressed cardiac output that leads to sympathetic nervous and inflammatory cytokine and system activity. Increased arteriolar vasoconstriction. Increased impedance to left ventricular ejection Decreased renal perfusion resulting in retention of salt and water with subsequent increase in cardiac filling pressures and congestion or edema.

Pathophysiology of Heart Failure Heart failure is difficult to simply define and is a wide spectrum of processes ranging from ischemia to myocardial toxins to volume or pressure overload and even genetic abnormalities that create the mileu of heart failure which is characterized by multiple neuro-endocrine, humoral and inflammatory feedback loops.

Cont’d As compensatory mechanisms themselves become problematic by exacerbating detrimental remodeling processes –Myocardial hypertrophy –Chamber enlargement Abnormalities characterizing heart failure should be considered physiologic, hormonal, cellular, subcellular, organelle, molecular biodynamic and genetic.

Cont’d Understanding the hallmark of cardiac response to injury, of myocyte growth and hypertrophy, interstitial fibrosis, apoptosis, sarcomere slippage and cardiac chamber enlargement is important when attempting to explain circulatory dysfunction. Heart failure should be described as –Acute or chronic –Right or left sided –Systolic or diastolic –Asymptomatic, minimally symptomatic or symptomatic

Blood Pressure Parameters BP=CO x TPR CO=HR x SV Carotid aortic baroreceptors and central nervous system and medullary vasomotor and cardiac centers modulate heart rate, PVR, cardiac contractility and venous tone which influences venous return and preload. Several factors are responsible for left ventricular diastolic dysfunction –Fibrosis and hypertrophy- increase diastolic chamber stiffness –Ischemia produces abnormalities of energy dependent relaxation Most cases of advanced symptomatic heart failure are a combination of significant systolic and diastolic dysfunction

Study shows that HF patients have lower oxygen carrying capabilities (VO2), decreasing exercise tolerance

HF patients are noted to have an inappropriate increase in PCWP and increased EDV

The flat stroke volume index curve is pathopneumonic of heart failure

HF Pt’s shows an increase in LVEDV consistently with a concomitant rise in PCWP with exercise

Myocyte Adaptation Protein turnover in normal myocyte is orderly and forms an adult myocyte and specific gene products Terminally differentiated post-natal myocytes are not capable of cell division Contractile proteins regenerate every days

Cell Membrane Receptors Activation of these receptors (GH, A2, NE, TNF- a, etc) precipitates second messengers such as cAMP, Inositol-Tri-Phosphate that then induces intracellular mediators such as phosphokinase C. The adult myocyte genetic program is induced by intramuscular mediators of gene activity such as C-fas, C-jun to produce adult and fetal muscle specific gene products. In heart failure this leads to unnatural growth of the cell that leads to hypertrophy and eventually apoptosis.

Cont’d The induction of fetal protein phenotype ultimately produces large myocytes that do not contract with normal vigor.

Necrosis and Apoptosis Both are important in the life and death cycle of the myocyte. Apoptosis- cell death by myocyte condensation without disruption of cell membrane. Eventually there is cell fragmentation with pinocytosis of cell content and phagocytosis of neighboring cells.

Cont’d Necrosis characterized by cell surface membrane disruption, inflammation and fibrotic replacement. In heart failure there may be acceleration of apoptosis (accelerated senescence).

Heart Failure Mileu A. Neurohumoral –With baroceptor dysfunction in heart failure there is excessive sympathetic activity with decreased parasympathetic activity. B. Kidney –Increased sympathetic activity is a potent stimulator of renin production C. B1 receptor density decreased –Alpha1 receptor density increased –AT1 receptor density decreased

Cont’d Nitric Oxide plays a role in sympathetic and parasympathetic autonomic responses. Inflammatory cytokines play a significant role in patients with heart failure (TNF-a. IL-1, IL-6, etc.).

Studies On LV Dysfunction (SOLVD) looks at vasoactive peptides norepi, renin, arginine vasopressin, and atrial natriuretic hormone

Importance of neuroendocrine receptors B1, B2, Alpha 1, and Angiotensin II specific receptors all play a key role in signal transductance at the myocyte surface generating specific proteins –Adenyl Cyclase (AC) –Ang II –Ang I –ATP –cAMP

The failing heart has fewer receptors